Truist Securities Upgrades Edwards Lifesciences to Buy, Raises Price Target to $113

Benzinga · 2d ago
Truist Securities analyst Richard Newitter upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $95 to $113.